Spyre Therapeutics, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Spyre raised ~$400M gross ($378M net) in October 2026 public offering, bringing pro forma cash to $1.5B with runway to H2 2029. Positive topline induction data announced for all three IBD monotherapies (SPY001, SPY002, SPY003) in SKYLINE Part A; Part B enrolling ahead of schedule with combination readout expected Q3 2027. SPY072 failed in RA (RA sub-study showed activity but below internal bar) and PsA/axSpA (missed primary endpoints); company discontinuing rheumatic disease development but pivoting to hidradenitis suppurativa with new SKYLIGHT trial.
Why this rating
Major capital raise (36% of market cap) extends runway significantly; IBD proof-of-concept achieved across monotherapies strengthens pipeline value. SPY072 failure in rheumatic diseases is offset by HS opportunity and combo focus, reducing downside risk.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.